US Broker Ratings

Keros Therapeutics, Inc. (KROS) Stock Analysis: A Biotech Play with Nearly 48% Upside Potential

Keros Therapeutics, Inc. (NASDAQ: KROS) stands out as an intriguing opportunity within the healthcare sector, particularly in the biotechnology industry. With a market capitalization of $631.57..

Capricor Therapeutics, Inc. (CAPR) Stock Analysis: Unveiling a Potential 246.80% Upside in the Biotechnology Sector

Capricor Therapeutics, Inc. (NASDAQ: CAPR) stands as a promising player in the biotechnology sector, gaining attention with a potential upside of 246.80% based on current analyst..

Eton Pharmaceuticals, Inc. (ETON) Stock Analysis: Exploring a Potential 67.88% Upside in the Rare Disease Market

Eton Pharmaceuticals, Inc. (ETON), a key player in the healthcare sector focusing on rare diseases, is gaining attention from investors due to its promising growth potential..

Oculis Holding AG (OCS): Analyst Consensus Points to 118% Upside in Biotech Innovator

Oculis Holding AG (OCS) is drawing significant attention from investors looking to capitalize on its promising pipeline in the biotechnology sector. Based in Zug, Switzerland, Oculis..

ArriVent BioPharma, Inc. (AVBP) Stock Analysis: Exploring a 102.64% Potential Upside in Biotechnology

ArriVent BioPharma, Inc. (AVBP) stands out in the biotechnology sector with its promising pipeline and strategic approach to address unmet medical needs in cancer treatment. Despite..

AMN Healthcare Services Inc (AMN) Stock Analysis: Navigating Challenges with Strategic Workforce Solutions

AMN Healthcare Services Inc (NYSE: AMN), a prominent player in the healthcare workforce solutions sector, stands at a pivotal point in its market journey. With a..

SI-BONE, Inc. (SIBN)

⚠️ No article content returned.

..

Savara, Inc. (SVRA) Stock Analysis: Unpacking the 145% Potential Upside in Rare Respiratory Therapy

Savara, Inc. (NASDAQ: SVRA), a biopharmaceutical company specializing in the development of therapies for rare respiratory diseases, is catching the eyes of investors with a substantial..

Taysha Gene Therapies, Inc. (TSHA): Investor Outlook with a 165% Potential Upside

Taysha Gene Therapies, Inc. (TSHA) is attracting considerable attention from investors, primarily due to its promising 165.85% potential upside, according to recent analyst estimates. This clinical-stage..

Embecta Corp. (EMBC) Stock Analysis: A Healthcare Player with a Promising 15% Upside

Embecta Corp. (NASDAQ: EMBC), a notable entity in the healthcare sector, is making waves with its focused approach on enhancing the lives of individuals living with..

Butterfly Network, Inc. (BFLY) Investor Outlook: Exploring a 106.97% Potential Upside

Butterfly Network, Inc. (NASDAQ: BFLY) is capturing the attention of investors with a significant potential upside of 106.97%, according to analyst ratings. This healthcare company, specializing..

Immunome, Inc. (IMNM) Stock Analysis: A Potential 140% Upside in the Biotechnology Sector

Immunome, Inc. (NASDAQ: IMNM) is catching the attention of investors in the biotechnology sector, promising a significant potential upside of 140.36%. Founded in 2006 and headquartered..

Simulations Plus, Inc. (SLP): Investor Outlook with a 79% Potential Upside

Simulations Plus, Inc. (NASDAQ: SLP) is making waves in the healthcare sector, particularly within the health information services industry. With a market capitalization of $284.19 million,..

Arcus Biosciences, Inc. (RCUS) Stock Analysis: 145% Potential Upside and Strong Buy Ratings

Arcus Biosciences, Inc. (NASDAQ: RCUS), a clinical-stage biopharmaceutical company, has been making waves in the biotech sector with its innovative cancer therapies. Headquartered in Hayward, California,..

AxoGen, Inc. (AXGN) Stock Analysis: Riding the Wave of an Impressive 60% Potential Upside

AxoGen, Inc. (NASDAQ: AXGN), a standout player in the healthcare sector, has captured the market’s attention with its innovative approach to peripheral nerve regeneration and repair...

Enhabit, Inc. (EHAB) Stock Analysis: Exploring a 19.27% Potential Upside

For investors interested in the healthcare sector, Enhabit, Inc. (NASDAQ: EHAB) presents a unique opportunity. Specializing in home health and hospice services, Enhabit operates within the..

Bicycle Therapeutics (BCYC): Riding a Potential 243% Upside with Innovative Biotech Solutions

Bicycle Therapeutics plc (NASDAQ: BCYC) has been capturing investor attention with its significant potential upside, reflected in an average analyst target price of $23.91, which suggests..

AnaptysBio, Inc. (ANAB) Stock Analysis: Unveiling a 115% Potential Upside in the Biotech Sector

AnaptysBio, Inc. (NASDAQ: ANAB), a clinical-stage biotechnology firm, is making waves in the healthcare sector with its innovative approach to immunology therapeutics. Headquartered in San Diego,..

Arbutus Biopharma Corporation (ABUS) Stock Analysis: Exploring a 30% Potential Upside in the Biotechnology Sector

Arbutus Biopharma Corporation (NASDAQ: ABUS), a prominent clinical-stage biopharmaceutical entity, is gaining attention in the biotechnology sector due to its potential upside. With a current market..

LENZ Therapeutics, Inc. (LENZ) Stock Analysis: Unveiling a 27% Upside Potential in the Biotech Sector

LENZ Therapeutics, Inc. (NASDAQ: LENZ) is making waves in the biotechnology sector, with a promising outlook that has captured the attention of investors. Headquartered in Solana..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds